<< VUCCC files for patent protection: New treatment regimen for Type 1 insulin-dependent diabetes | NextGen Healthcare Information Systems wins MS-HUG 2010 Innovation Awards for Interoperability/HIE >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Ελληνικά | Norsk | Русский | Svenska | Polski

Blood glucose-lowering hormone FGF21 also activates brown adipose tissue metabolism

Published on March 3, 2010 at 7:36 AM · No Comments

The blood glucose-lowering hormone FGF21 is also an activator of brown adipose tissue metabolism, according to the study featured on the cover of Cell Metabolism and directed by the lecturer Francesc Villarroya of the UB's Department of Biochemistry and Molecular Biology (Faculty of Biology),  the Institute of Biomedicine, and the Biomedical Research Networking Centre in Physiopathology of Obesity and Nutrition.

The study was carried out using newborn mice, and reveals possible new therapeutic targets for combating obesity using the fibroblast growth factor 21 (FGF21), which is secreted by the liver in response to fats in the diet. The team behind the research describe a novel action of FGF21 on brown adipose tissue, which governs energy expenditure and heat production in the body.

FGF21 is an antidiabetic and antiobesity agent that has been referred to in scientific literature since 2005", says Francesc Villarroya, an expert in the study of metabolism regulation models using genetically modified mice. He explains that, "Our study provides the first evidence that FGF21 causes thermogenesis in brown adipose tissue, that is, the burning of calories to release heat, dissipating large amounts of energy. Any agent that promotes and activates brown adipose tissue metabolism is, by definition, an antiobesity agent".

One of the major contributions of the study is the discovery of a direct link between FGF21 and brown adipose tissue. As Villaroya explains, "In in vivo studies we saw that the factor activates thermogenesis in brown adipose tissue. In the standard model, this process was regulated by the brain via an adrenergic pathway, but in new in vitro studies we have seen that the target of FGF21 was in fact not the brain but the brown adipose tissue. If FGF21 acts directly on brown adipose tissue and is independent of adrenergic control, we will have new ways of exploring mechanisms for controlling body fat".

The article examines the biological activity of EFG21 in a new model: newborn animals. "The work with newborn animal models is another crucial aspects of the study", says Villarroya, "We know that metabolic alterations during the foetal and neonatal stages have an impact on metabolism in the adult. In the case of mice, during the foetal stage they are fed by maternal glucose through the placenta. After birth, the mouse feeds on maternal milk rich in fats, which it must begin to metabolize. Therefore, newborn mice are excellent models for studying the process of adaptation to new metabolic demands".

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading